Abstract
BackgroundThe transcription factor PAX6 is primarily expressed in embryos. PAX6 is also expressed in several tumors and plays an oncogenic role. However, little is known about the role of PAX6 in lung cancer.MethodsThe function of PAX6 in lung cancer cells was evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation, anchorage-independent growth, and cell cycle arrest. The changes of cyclin D1, pRB, ERK1/2, p38 expression caused by PAX6 inhibition were detected using western-blotting. The PAX6 mRNA level in 52 pairs of tumors and corresponding matched adjacent normal tissues from non-small cell lung cancer patients and lung cancer cell lines was detected by real-time PCR.ResultsSuppression of PAX6 expression inhibited cell growth and colony formation in A549 and H1299 cells. The percentage of cells in G1-phase increased when PAX6 expression was inhibited. The cyclin D1 protein level, as well as the pRB phosphorylation level, decreased as a result of PAX6 down-regulation. The activity of ERK1/2 and p38 was also suppressed in PAX6 knock-down cells. The PAX6 mRNA was highly expressed in lung cancer tissue and lung cancer cell lines. In most patients (about 65%), the relative ratio of PAX6 mRNA in primary NSCLC versus adjacent tissues exceeded 100.ConclusionsOur data implicated that PAX6 accelerates cell cycle progression by activating MAPK signal pathway. PAX6 mRNA levels were significantly elevated in primary lung cancer tissues compared to their matched adjacent tissues.
Highlights
A recent overview on global cancer statistics showed that lung cancer was the most commonly diagnosed cancer, as well as the leading cause of cancer death [1]
RPMI 1640, fetal bovine serum (FBS), and Trizol Reagent were purchased from Invitrogen (Carlsbad, CA); M-MLV reverse transcription, CellTiter 96H aqueous non-radioactive cell proliferation assay, oligo-dT, and dNTP were obtained from Promega (Madison, WI); SYBRH Green PCR Master Mixture was from Applied Biosystems (Carlsbad, CA); anti-PAX6 antibodies were purchased from Abnova (Taibei, Taiwan), anti-pRB, -ERK1/2, p38, -pERK, -pp38, -cyclin D1, and -pRB (S780 phosphorylation) antibodies were obtained from Abcam (Cambridge, England, UK); and enhanced chemiluminescence (ECL) reagent was obtained from Pierce (Rockford, IL)
To elucidate whether PAX6 expression has any effect on the growth of lung cancer cells, RNA interference (RNAi) was used to generate pax6 knock-down (PAX6 KD) cell lines
Summary
A recent overview on global cancer statistics showed that lung cancer was the most commonly diagnosed cancer, as well as the leading cause of cancer death [1]. It is important to find which pathways or proteins are active in lung tumor progression [3]. On the basis of the "cancer stem cell hypothesis," tumors are thought to originate through tissue-specific stem cell expression [4,5,6]; in other words, tumors are attributed to stem cell factor overexpression [3,5,7]. Pairedbox 6 (Pax6) is an important transcription factor during embryogenesis and a stem cell factor [3]. PAX6 may play an important role in tumorigenesis. The transcription factor PAX6 is primarily expressed in embryos. PAX6 is expressed in several tumors and plays an oncogenic role. Little is known about the role of PAX6 in lung cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
